# Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

> **NCT00358228** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 787 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** Rimonabant

## Key facts

- **NCT ID:** NCT00358228
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358228, "Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00358228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*